- Review of interventions
- Open Access
Reducing stillbirths: interventions during labour
BMC Pregnancy and Childbirthvolume 9, Article number: S6 (2009)
Approximately one million stillbirths occur annually during labour; most of these stillbirths occur in low and middle-income countries and are associated with absent, inadequate, or delayed obstetric care. The low proportion of intrapartum stillbirths in high-income countries suggests that intrapartum stillbirths are largely preventable with quality intrapartum care, including prompt recognition and management of intrapartum complications. The evidence for impact of intrapartum interventions on stillbirth and perinatal mortality outcomes has not yet been systematically examined.
We undertook a systematic review of the published literature, searching PubMed and the Cochrane Library, of trials and reviews (N = 230) that reported stillbirth or perinatal mortality outcomes for eight interventions delivered during labour. Where eligible randomised controlled trials had been published after the most recent Cochrane review on any given intervention, we incorporated these new trial findings into a new meta-analysis with the Cochrane included studies.
We found a paucity of studies reporting statistically significant evidence of impact on perinatal mortality, especially on stillbirths. Available evidence suggests that operative delivery, especially Caesarean section, contributes to decreased stillbirth rates. Induction of labour rather than expectant management in post-term pregnancies showed strong evidence of impact, though there was not enough evidence to suggest superior safety for the fetus of any given drug or drugs for induction of labour. Planned Caesarean section for term breech presentation has been shown in a large randomised trial to reduce stillbirths, but the feasibility and consequences of implementing this intervention routinely in low-/middle-income countries add caveats to recommending its use. Magnesium sulphate for pre-eclampsia and eclampsia is effective in preventing eclamptic seizures, but studies have not demonstrated impact on perinatal mortality. There was limited evidence of impact for maternal hyperoxygenation, and concerns remain about maternal safety. Transcervical amnioinfusion for meconium staining appears promising for low/middle income-country application according to the findings of many small studies, but a large randomised trial of the intervention had no significant impact on perinatal mortality, suggesting that further studies are needed.
Although the global appeal to prioritise access to emergency obstetric care, especially vacuum extraction and Caesarean section, rests largely on observational and population-based data, these interventions are clearly life-saving in many cases of fetal compromise. Safe, comprehensive essential and emergency obstetric care is particularly needed, and can make the greatest impact on stillbirth rates, in low-resource settings. Other advanced interventions such as amnioinfusion and hyperoxygenation may reduce perinatal mortality, but concerns about safety and effectiveness require further study before they can be routinely included in programs.
Stillbirths, or late fetal deaths, account for more than half of the world's 6 million perinatal deaths that occur in low-/middle-income countries each year. While stillbirth rates are commonly as low as 3 to 5 per 1000 births in some high-income countries, their incidence is estimated to be five to ten times greater in many low-/middle-income countries. These higher stillbirth rates are believed to be attributable to poor baseline maternal health (especially nutritional status), poor prevention and treatment of maternal conditions and infections during pregnancy, and inappropriate management of complications during pregnancy and childbirth.
There are two kinds of intrauterine fetal deaths: those that occur prior to the onset of labour (antepartum stillbirths), and those that occur during labour (intrapartum stillbirths). The major causes of antepartum stillbirths are pregnancy complications that lead to fetal asphyxia and/or infection, including maternal infections, hypertensive disorders, placental dysfunction and haemorrhage, and fetal or placental abnormalities. The specific causes of many antepartum stillbirths, however, are difficult to ascertain. In low-/middle-income countries, approximately one-third of stillbirths are estimated to occur intrapartum, and these are caused primarily by complications arising during labour and childbirth, such as prolonged or obstructed labour or umbilical cord accidents [1, 2].
Intervention strategies to prevent antepartum and intrapartum stillbirths differ because they have largely different causes. Where women receive quality intrapartum care, as in many high-income countries, the proportion of intrapartum stillbirths is less than 10% of all stillbirths , indicating that a substantial proportion of intrapartum stillbirths are preventable with quality intrapartum care. Yet half of the world's women give birth at home, in the absence of a skilled birth attendant. Globally, the intrapartum stillbirth rate is estimated to be between 7 and 9 per 1000 births [2–4], but this figure obscures wide disparities both within and among countries, including substantial urban-rural and rich-poor divides. The risk of an intrapartum stillbirth in low and middle-income countries is more than 14 times that in high-income countries; the risk is 17 times higher in low-income than in middle-income countries. When women in low-/middle-income countries do give birth in health facilities, their care and their pregnancy outcomes are frequently compromised by absent or overburdened health care providers; deficiencies in training and supervision; insufficient supplies, drugs, and equipment; and substandard hygienic practices.
This paper focuses on interventions delivered during childbirth, primarily care provided at secondary- and tertiary-level large teaching and research hospitals with surgical capacity, that are of potential benefit for perinatal health and prevention of stillbirths.
Detailed methods undertaken to assemble and assess the evidence for the interventions in this paper are given in the first paper in this series . Each study was given a level of evidence (LOE) according to the SIGN grading system. Grade of evidence, (i.e. A, B, C, D) was determined and then the interventions were classified under clear evidence, some evidence, uncertain evidence or evidence of no or negative impact, as detailed in paper 1 . We included 8 obstetric care interventions in our analysis (Table 1).
Instrumental delivery (vacuum and forceps-assisted)
Instrumental vaginal deliveries, which make up a subset of operative deliveries, are procedures involving traction applied to the fetal head, for indications including maternal exhaustion or other compromise (e.g., maternal heart disease), fetal distress or heart rate abnormalities (often associated with prolonged second stage of labour), and fetal malposition . Rates of instrumental deliveries range from 5–20% in high-income countries . Before an instrumental delivery should be attempted, the fetal head must be engaged and its position known, the cervix fully dilated, and the membranes ruptured. Traction is generally applied to the fetal head with either forceps or a vacuum extraction device (also called a ventouse). The use of these devices poses the potential for injury to the mother or the baby. Forceps have long been associated with birth trauma, particularly when used for rotational procedures, but low overall morbidity rates are reported for well-trained forceps practitioners . While the association with birth injury is fairly well established, whether forceps use or vacuum extraction is preferable for preventing stillbirth or perinatal mortality is unclear.
Our systematic review included 2 Cochrane reviews and 5 other observational and intervention studies (Table 2). No studies were found that compared stillbirth outcomes with versus without instrumental vaginal delivery. One Cochrane review by Johanson et al.  compared the impact of vacuum extraction to forceps delivery, and included 7 trials reporting perinatal mortality outcomes (Additional file 1). Vacuum extraction compared to forceps delivery was associated with significantly less maternal trauma (OR = 0.41, 95% CI: 0.33–0.50) and less general and regional anaesthesia. Additionally, the risk of Caesarean section showed a trend towards being lower among the vacuum extractor group than the forceps group (OR = 0.56, 95% CI: 0.31–1.02 [NS]). Vacuum extraction was more likely to fail when used for assisted vaginal delivery than forceps (OR = 1.69, 95% CI: 1.31–2.19). Perinatal mortality rates were not statistically significantly different between the two instrumental methods (7 trials, N = 1800, OR = 0.80, 95% CI: 0.18–3.52 vacuum extraction vs. forceps, respectively). The vacuum extractor was associated with an increase in neonatal cephalhaemotomas and retinal haemorrhages, but serious neonatal injury was uncommon with either instrument and Apgar scores at 1 and 5 min were comparable [LOE: 1+]. The other Cochrane review, also by Johanson et al. , compared the impact of use of soft versus rigid vacuum extractor cups; only one trial (N = 72) in Malaysia reported perinatal death as an outcome but found no significant difference between soft and hard cups (OR = 1.26, 95% CI: 0.08–20.85 [NS]) [LOE: 1+](Additional file 2).
An RCT by Weerasekera et al.  not included in the above reviews compared the outcomes associated with vacuum and forceps deliveries (N = 442 women) in the second stage of labour. There were no significant differences between the two methods in the incidence of third-degree perineal tears, postpartum haemorrhage or ruptured uterus, but cervical tears were slightly higher in the forceps group. Cephalhaematoma incidence was higher among the vacuum extraction group, but there were no significant differences between the groups in babies needing resuscitation at birth, admission to neonatal intensive care unit, stillbirth or neonatal death rates [LOE: 2+]. Another RCT from Pakistan reported similar success rates with both instruments .
Multiple observational studies have evaluated the complications and outcomes related to vacuum deliveries either alone or in comparison with alternative methods of instrumental deliveries [11, 12]. In a prospective study of 167 vacuum extractions (6.3% of total deliveries) at the national hospital in Kenya, Gachiri et al.  documented perinatal morbidity and mortality rates of 16.2% and 4.8% respectively [LOE: 3]. Lurie et al  conducted a decision-to-delivery time analysis and found that it was faster to undertake forceps deliveries compared to vacuum extractions. While some studies suggested higher rates of vaginal tears with forceps , in general no differences in complication rates were found in other studies , and no studies found differences in stillbirth incidence.
We identified 7 trials comparing vacuum extraction versus forceps-assisted deliveries that reported stillbirth incidence (N = 632 vacuum, N = 611 forceps). Our meta-analysis found no evidence of differential impact of either method on stillbirths (OR = 0.60, 95% CI: 0.07–5.00) (Figure 1).
Although vacuum extraction was associated with a trend toward lower Caesarean section rates and fewer significant maternal injuries and less anaesthetic requirement than forceps delivery, there was no difference in rates of intrapartum stillbirth or perinatal mortality. Vacuum extraction tended to be associated with increased, albeit low, risk of neonatal cephalohaematoma and retinal haemorrhage. The lower rate of Caesarean section despite higher failure rate among vacuum extractions may be due to superiority of the vacuum for managing certain fetal malpositions (such as deflexed occipital posterior position, for example), or more likely, because following a failed vacuum extraction, delivery is usually by forceps, while failed forceps is usually followed by Caesarean section [7, 17]. The reduced maternal morbidity and limited, largely short-term risk of neonatal complications associated with vacuum extraction suggest that although there is no evidence that either method is superior to the other in preventing stillbirths, vacuum extraction may be preferable in areas where vacuum extractors are available and practitioners are suitably trained to perform vacuum extraction . In other areas where forceps deliveries are the norm and health practitioners do not have training in vacuum extraction, the significant investment needed for the purchase of vacuum extractors and quality training to capacitate practitioners to perform the procedure may be prohibitive for certain low-resource settings. Relatively inexpensive manual vacuum extractors are available that may require less training to use than forceps and may be a useful alternative to forceps to facilitate rapid delivery in the presence of signs of fetal distress in the second stage of labour; however, these require further evaluation.
Emergency obstetric care, including Caesarean section
The vast majority of the world's one million intrapartum stillbirths each year occur in low-/middle-income countries marked by high rates of unmet obstetric need [18, 19], suggesting that many of these deaths could be prevented with improved obstetric care [20, 21]. The availability of comprehensive essential obstetric care (EOC), supported by emergency transport, skilled providers, and aftercare, is regarded as critical for effective maternal health services in obstetric emergencies . Essential obstetric care (EOC) refers to elements of obstetric care needed for the management of normal and complicated pregnancy, delivery and the postpartum period. Basic EOC can be performed in primary health care facilities, and includes administration of anti-biotics, oxytocics, anti-convulsants including magnesium sulfate, manual removal of the placenta, treatment for incomplete miscarriage, post-abortion care, and instrumental vaginal delivery with forceps or vacuum extractor. Comprehensive EOC includes all basic EOC functions plus Caesarean section, anaesthesia, and blood transfusion, and generally requires a secondary or higher-level health facility. The subset of comprehensive EOC interventions used to respond to unexpected intrapartum complications such as haemorrhage and obstructed labour is referred to as emergency obstetric care (EmOC) , and includes some elements of basic EOC such as manual removal of the placenta and medical treatment in labour, as well as all anaesthesia, blood transfusion, and Caesarean section.
Non-availability of EmOC, especially Caesarean section, in resource-poor settings has been implicated as a risk factor for intrapartum stillbirths, particularly those associated with prolonged labour and its associated fetal asphyxia, infection, and birth trauma [24–28]. Reductions in intrapartum stillbirth rates observed in the UK have been attributed to more liberal use of Caesarean section , though this is controversial. There is evidence to suggest that the optimal Caesarean section rate to reduce the number and proportion of intrapartum stillbirths lies between 5 and 10 percent . Recent data from global estimates of Caesarean section availability at population level indicate that many countries fall far short of this range, while others exceed this, to the possible detriment of maternal health outcomes . Some studies have shown that it can be comparatively safe to deliver in rural hospitals even if they lack Caesarean section capability .
Quality of EmOC is also critical. These issues have been documented in high-income countries, particularly among rural populations [26, 31, 32], but the data associating quality of EmOC with stillbirth or perinatal mortality rates has not been compiled.
Because the components of EmOC are by definition life-saving interventions, RCTs of EmOC versus no EmOC would be unethical, so the evidence base for improving access to and quality of EmOC, especially Caesarean section, consists largely of observational studies.
The literature on EmOC considered two primary issues: availability and optimal rates of Caesarean section (and associations with intrapartum stillbirth rates); and the impact of quality of obstetric care on perinatal outcomes. We identified 40 studies reporting stillbirth or perinatal mortality outcomes that reviewed or implemented interventions to provide EmOC (Table 3).
Availability and practice of Caesarean section
In low-/middle-income countries, prolonged and/or obstructed labour complicated by fetal asphyxia, fetal or placental infection, and birth trauma is a major cause of stillbirth, often arising from a small maternal pelvis due to childhood malnutrition, which subsequently leads to cephalopelvic disproportion during delivery . Timely delivery, often by Caesarean section or instrumental vaginal delivery, can reduce associated intrapartum stillbirth, and is largely credited for the relatively low rates of intrapartum stillbirth in high-income countries .
Using regression analysis of data from WHO and other sources to examine the association between stillbirth rates and obstetric care, Goldenberg et al.  and McClure et al.  observed that Caesarean section availability in low-/middle-income countries was associated with reductions in intrapartum stillbirths (Figures 2, 3 and 4). They  reported that intrapartum stillbirths dropped by 1.61 per 1000 births for every one percentage point increase in Caesarean section from 0 to 8 percent. Thereafter, they observed a small, non-significant increase in intrapartum stillbirths for each percent increase in Caesarean section. Intrapartum stillbirth rates correlated more closely with the measures of obstetric care in the regression analysis than did antepartum stillbirth rates, corroborating the theory that obstetric care availability and quality improvements will impact intrapartum stillbirth incidence more than antepartum stillbirth incidence. There was no relationship between Caesarean section and intrapartum stillbirths in high-income countries, which all had rates of Caesarean section of 15 percent or more. The WHO recommends Caesarean section rates of 10 to 15 percent, although they also note that 'countries with some of the lowest perinatal mortality rates in the world have a Caesarean rate of less than 10 percent,' and that perinatal mortality declines are steep until Caesarean section rates reach approximately 8 percent of deliveries, after which point the relationship becomes less clear 
Using data from the early 1980s in Australia, Alessandri et al.  performed a case-control study of intrapartum stillbirths, and could not identify any specific antenatal risk factors that predicted these demises. However, they did suggest that because the odds of emergency Caesarean section were significantly higher among stillbirth cases than live born controls, prompt Caesarean section might reduce intrapartum stillbirths, the risk of which was strongly associated with placental abruption or other placental problems, fetal distress, umbilical cord prolapse, and vaginal breech delivery. Other studies have confirmed that in many high-income country settings, liberal policies of Caesarean section are associated with positive effects on fetal survival, even when performed well before term [36–39].
While Caesarean section can be a life-saving intervention for both mother and child, its liberal use exposes some proportion of mothers and babies who do not need the procedure to unnecessary risks of morbidity. Additionally, in some low-/middle-income countries, particularly in low-resource areas, there is some evidence that the practice of Caesarean section may be associated with an increased risk of perinatal mortality [40, 41], suggesting that Caesarean section may be performed too late or by inadequately skilled practitioners in these settings. Additionally, the elevated risk of uterine rupture in subsequent pregnancies after a Caesarean section should be a consideration in providing the procedure in remote areas. In addition to the risk of uterine rupture, the data are conflicting about whether vaginal labour after previous Caesarean is associated with increased risk of perinatal mortality [42–46]. Because of the known risk of uterine rupture, particularly among women whose prior Caesarean incision was classical rather than lower-segment, it is recommended that women who have had prior classical Caesarean section have immediate access to EmOC in subsequent pregnancies to reduce the risk of maternal mortality and stillbirth.
Quality of obstetric care
A number of studies associated suboptimal care, particularly inadequate, inappropriate, or delayed care of complications such as obvious fetal distress, placental abruption, breech presentation, twin pregnancy, or eclampsia, with increased perinatal mortality [47, 48]. Several studies comparing hospitals or assessing health systems found that quality of care provided in facilities was directly associated with perinatal mortality [49–51, 25]. Recent improvements in term stillbirth rates, especially intrapartum stillbirths, suggest that more rapid performance of Caesarean section in cases of placental abruption has resulted in a lower incidence of abruption-associated stillbirth . In Virginia, USA, Cruikshank and Linyear  observed that intrapartum stillbirths associated with abruption were characterised by a fairly long delay between the appearance of fetal compromise and delivery, suggesting that timely Caesarean section could have prevented these deaths. In Finland, Korhonen and Kariniemi  found that having a surgical team in-hospital to perform Caesarean sections versus having the team on-call resulted in lower perinatal mortality (P = 0.05) and prevented all cases of fetal death and hypoxic ischemic encephalopathy (versus 3/41 in controls and 1/41 in controls, respectively).
Jehan et al.  recently reviewed stillbirths in rural Sindh Province, Pakistan, and found that a large proportion of these stillbirths occurred in facility settings with ostensibly skilled care providers. Because the rate of fetal mortality in labour seems to be reduced with adequate care, Kiely et al  have proposed using fetal deaths in labour as an epidemiologic measure of the quality of obstetric care. They found that delivery in a level 1 (primary care) hospital was associated with a 60% increase in intrapartum stillbirth compared to a level 3 facility (equipped for perinatal intensive care). Similarly, a retrospective analysis  found that rural residence was associated with elevated stillbirth rates (OR = 1.20; 95% CI: 1.09–1.32, P < 0.001) and neonatal death in hospital (adjusted OR = 1.26; 95% CI: 1.07–1.48) compared to urban residence, which granted women better access to higher-level emergency obstetric care.
There is some limited evidence that Caesarean section capability is not the only component of EmOC with the potential to reduce perinatal mortality. Advances in labour management and perinatal care have also contributed to significant declines in perinatal mortality. Steyn et al  observed that over a 20-year period in South Africa, the Caesarean section rate remained constant, but perinatal mortality decreased by 50 percent. In a remote area of the US in a high-risk Native American obstetric population, Leeman et al  documented a Caesarean section rate one-third of the national average without any adverse impact on perinatal mortality rate (PMR), which was the same as the national average. Even in remote areas without Caesarean section capability, intrapartum stillbirths and perinatal deaths can be significantly reduced with improved quality of obstetric and perinatal care alone. Grzybowski  undertook a prospective study to determine whether a small, isolated hospital without Caesarean section capability and which handled fewer than 50 births annually could provide safe obstetric and perinatal care. Over the 5-year study period, there were 6 perinatal deaths, for a perinatal mortality rate of 20.8 per 1000 (95% CI: 4.4–37.2 per 1000); however, the wide confidence intervals indicate the study was underpowered to measure perinatal mortality, and the perinatal mortality rate was still more than double that of many high-income countries, including the US .
While varied in design and lacking the rigor of RCTs, evidence from available, largely observational studies, taken together, indicates that availability of facilities capable of providing EmOC with trained care providers who are able to undertake safe and timely Caesarean section for appropriate indications is critical for reducing the risk of intrapartum stillbirths. It is not possible, however, based on the available data to ascertain the relative contribution of various components of EmOC to the mortality reductions observed. The need for Caesarean section capacity in rural settings is apparent from the data. The risk of uterine rupture and placental invasion of the uterine scar, and the higher rate of stillbirth in subsequent pregnancies after Caesarean section  suggests that liberal Caesarean section policies are unjustifiable, especially where access to emergency obstetric care is limited or home birth is common. Medically unnecessary Caesarean sections would place a large group of women at risk of uterine rupture if they do not or cannot access EmOC in subsequent pregnancies. A Caesarean section rate of 10–15% as recommended by WHO appears appropriate, particularly in resource-constrained settings; it is paramount that the procedure is performed for indications of fetal distress or other standard indications, rather than for the convenience of the provider or on maternal request. Additionally, several studies reported significant improvement in perinatal mortality rates in facilities without Caesarean section capability, and others demonstrated that Caesarean section provided too late or in too remote a setting increased perinatal mortality, suggesting that quality of obstetric care, rather than mere availability of Caesarean section, is key in preventing stillbirths and perinatal deaths. Despite the obvious lack of RCTs, the evidence in support of increased emergency Caesarean section availability to reduce stillbirths is strong (Grade B); EmOC is needed in all low-/middle-income country health systems.
Induction of labour (versus expectant management)
Induction of labour, a common intervention in obstetric practice, is indicated when it is determined that the fetus or mother will more likely have a healthy outcome than if birth is delayed. While many studies have compared different regimens and administration techniques of drugs to ripen the cervix and induce labour, few have evaluated the outcomes associated with induction versus expectant management of spontaneous labour for different indications . Induction is frequently practised at term or post-term, or in cases in which the fetus is suspected to be macrosomic and therefore likely to require complicated operative delivery . Additional common indications for induction of labour include pre-eclampsia, cases of premature rupture of membranes (PROM) where labour does not quickly become spontaneously established thereafter, and twin pregnancy. The process of induction of labour should only be considered when vaginal delivery is felt to be the appropriate route of delivery. Many different agents and methods can be used to induce and augment labour, including drugs such as oxytocin or prostaglandins, and physical interventions including sweeping the membranes or early amniotomy. Little is known about the impact of induction for different indications on stillbirth and perinatal outcomes.
Our literature search identified 5 Cochrane reviews and 3 other interventional/observational studies (Table 4).
Post-term pregnancy/prevention of obstructed labour due to cephalo-pelvic disproportion
Considering the merits of induction in post-term pregnancies, Gülmezoglu et al.  reported a non-significant reduction in stillbirth risk (RR = 0.28, 95% CI: 0.05–1.67, 12 trials, N = 5939 women), but a statistically significant reduction in perinatal mortality (RR = 0.30, 95% CI: 0.09–0.99, 12 trials, N = 5939 women), in induced versus expectantly managed groups [LOE: 1+](Additional file 3).
Irion et al.  (Additional file 4) reviewed three trials involving 372 non-diabetic women who underwent induction of labour for suspected fetal macrosomia. Compared to expectant management, induction of labour for suspected macrosomia did not reduce risk of Caesarean section (RR = 0.96, 95% CI: 0.67–1.38) or instrumental delivery (RR = 1.02, 95% CI: 0.60–1.74) [LOE: 1++].Boulvain et al.  (Additional file 5) conducted a review of elective delivery, either by induction of labour or by elective Caesarean section, compared to expectant management, and included one trial  which compared a policy of active induction of labour at 38 weeks to expectant management until 42 weeks. The risk of Caesarean section was not statistically different between groups (RR = 0.81, 95% CI: 0.52–1.26), but the risk of fetal macrosomia was reduced in the active induction group (RR = 0.56, 95% CI: 0.32–0.98). No other perinatal morbidity was reported [LOE: 1-].
Premature rupture of membranes (PROM)
Dare et al.  conducted a Cochrane review to assess the effects of induction of labour versus expectant management among women with premature rupture of membranes (PROM) at term (12 RCTs, N = 6814 women) (Additional file 6). They found that planned management generally involved induction with oxytocin or prostaglandin; one trial used homoeopathic caulophyllum. Significantly fewer women in the induced compared with the expectant management groups developed chorioamnionitis (RR = 0.74, 95% CI: 0.56–0.97; 9 trials, 6611 women) or endometritis (RR = 0.30, 95% CI: 0.12 to 0.74; 4 trials, 445 women). There was a non-significant trend toward lower perinatal mortality (OR [fixed]: 0.46, 95% CI: 0.13–1.66) and neonatal infection incidence (RR = 0.83, 95% CI: 0.61–1.12; 9 trials, 6406 infants) in the induced versus the expectantly managed groups. There was no difference between the two groups in Caesarean section rates (12 trials, N = 6814 women, RR = 0.94, 95% CI: 0.82–1.08) or operative vaginal birth (7 trials, N = 5511 women, RR = 0.98, 95% CI: 0.84–1.16) [LOE: 1+].Another Cochrane review on induction of labour for pre-term PROM (prior to 37 weeks of gestation) is in progress . An intervention study from Brazil  not included in the above Cochrane review reported no difference in fetal deaths among a group of women with PROM at term (N = 150) given vaginal misoprostol vs. those managed expectantly for 24 hours, then given intravenous oxytocin [LOE: 1+].
Dodd et al.  investigated the optimal timing of elective induction of labour after 37 weeks in twin pregnancy (N = 72 women) and reported no statistically significant differences between a group electively induced at 37 weeks versus an expectantly managed group; the study was underpowered to detect true differences in perinatal mortality rates [LOE: 1-](Additional file 7).
Several other intervention and observational studies not included in the Cochrane reviews addressed the impact of induction of labour on perinatal outcomes. In Saudi Arabia among a group of grand multiparas at term, Chattopadhayay et al.  reported a lower stillbirth rate in a group receiving intracervical prostaglandin E2 tablets compared to a group in which labour was managed expectantly (SBR: 0/150 vs. 4/150 in prostaglandin versus expectantly managed groups, respectively; no statistical significance data given).
We conducted a meta-analysis of trials (3 RCTs, N = 1770 women) of planned induction of labour using prostaglandins versus expectant management in women with PROM. No significant decrease in perinatal mortality was found (OR = 0.50, 95% CI: 0.05–5.53) in the planned induction versus expectantly managed groups, respectively (Figure 5).
The evidence from this review indicates that induction of labour does not impact the likelihood of delivery by Caesarean section. Two trials, however, showed a significant reduction in the risk of Caesarean section from a policy of routine induction of labour among low-risk women with post-term pregnancy [72, 73], though performance bias may have skewed the results in the Hannah trial.
Induction of labour for suspected fetal macrosomia in non-diabetic women has not been shown to alter the risk of maternal or neonatal morbidity, but the power of the included studies to show a difference in rare events is limited. Large trials are ongoing to address this question. Induction of labour appears to be an appropriate intervention in post-term pregnancy at 41 completed weeks of gestation or later. The Cochrane review by Gülmezoglu et al.  comparing elective induction of labour with expectant management showed a statistically significant reduction in perinatal mortality and meconium aspiration syndrome. Although increasingly more commonplace, elective inductions are not advised before 39 weeks gestation given the potential, albeit low, for complications associated with prematurity. Even in cases of post-term pregnancy, 500 inductions may be required to prevent one perinatal death. The reduction in stillbirth incidence noted in the Gülmezoglu review was not statistically significant, likely because the number of stillbirths was too small.
Larger RCTs are needed to address the impact of induction of labour on stillbirth and perinatal mortality for the following indications: suspected macrosomia in non-diabetic mothers, multiple pregnancy, and mild pre-eclampsia.
Drugs for cervical ripening and induction of labour
There are a variety of drugs, including oxytocin and a number of prostaglandins and prostaglandin analogues, and many different administration methods including intracervical, vaginal, oral, and intravenous (IV) routes, for the induction of labour. Drugs to induce labour can have adverse side effects, fail to induce labour, or cause dysfunctional labour or hyperstimulation of the uterus leading to fetal distress and Caesarean section. Fetal and possibly maternal death is possible if Caesarean section is not available or delayed when these drugs are used. The state of cervical ripening and favourability for induction should be assessed before a regimen is selected, as oxytocin induction, in particular, often fails unless the cervix is ripe. In women with unfavourable cervical ripening, different prostaglandin drugs, including prostaglandin F2-alpha, prostaglandin E2 (dinoprostone), and prostaglandin E1 (misoprostol) promote cervical ripening and initiation of labour . Misoprostol is the only prostaglandin analogue that is effective in inducing labour without gastrointestinal side effects when given as an oral preparation. It is inexpensive and stable at room temperature, making it an easily administered intervention appealing for use in low-resource settings, though the risk of uterine hyperstimulation at high doses may produce increased risk of maternal or perinatal death . Insertion of a Foley catheter has also been shown to be as effective as prostaglandin E2 for stimulating preinduction cervical ripening, potentially providing an effective, safe, non-pharmacological mechanical method of preinduction cervical ripening [76–78].
Given the use of induction for certain indications including post-term pregnancy, pre-eclampsia, and PROM in which the fetus is at higher risk of perinatal death, as well as the potential for drugs used to induce labour to cause fetal distress, an assessment of the evidence of impact of specific drugs available for induction of labour on perinatal outcomes is warranted.
Our literature search identified 8 Cochrane reviews and 11 other studies (Table 5) assessing the impact of different drugs for cervical ripening and/or induction of labour. The trials identified are grouped below by the drugs being compared and the route of administration.
Oral misoprostol versus placebo, other prostaglandins, or vaginal misoprostol
Alfirevic et al.  (Additional file 8) conducted a Cochrane systematic review of all trials (41 trials, N = 8606 women) comparing oral misoprostol with various other drugs for induction of labour. No studies comparing oral misoprostol to placebo reported perinatal outcomes. Comparing oral misoprostol with vaginal prostaglandin E2, there was no significant reduction in risk of perinatal mortality (5 trials, N = 2249, RR = 0.60, 95% CI: 0.08–4.50); risk of Caesarean section (9 trials, N = 2627 participants) reached statistical significance only in the subgroup with intact membranes (RR = 0.78, 95% CI: 0.66–0.94). Uterine hyperstimulation was more common after oral misoprostol (RR = 1.63, 95% CI: 1.09–2.44) although this was not associated with any adverse fetal events. Comparing oral misoprostol versus vaginal misoprostol preparations, the meta-analysis found no difference in perinatal outcomes (16 trials, N = 3645 participants) [LOE: 1++].
Vaginal misoprostol versus placebo, other prostaglandins, or oxytocin
A Cochrane review by Hofmeyr et al.  (Additional file 9) evaluated 70 RCTs to determine the impact of vaginal misoprostol for cervical ripening or induction of labour. Compared to placebo, vaginal misoprostol was associated with increased success in achieving vaginal delivery within 24 hours (RR = 0.36, 95% CI: 0.19–0.68), but the risk of uterine hyperstimulation without fetal heart rate changes was increased (RR = 11.66, 95% CI: 2.78–49). Only one study reported perinatal mortality and uterine rupture as outcomes, risk ratios were not determined. The findings were similar when vaginal misoprostol was compared with vaginal prostaglandin E2, intracervical prostaglandin E2, and oxytocin, though none of these interventions had any differential impact on perinatal outcome. Many studies were small and reported no perinatal deaths in either group. Compared with vaginal or intracervical prostaglandin E2, oxytocin augmentation was less common and meconium-stained liquor more common with misoprostol [LOE: 1+].
Our literature search identified additional RCTs and a cohort study not included in the above-mentioned Cochrane review comparing vaginal misoprostol with vaginal prostaglandin E2; all indicated no significant differences in neonatal outcomes, and none specifically reported stillbirth rates. RCTs by Garry et al [LOE: 1-]and Lokugamage et al. [LOE: 1-]compared vaginal misoprostol versus vaginal prostaglandin E2 inserts for cervical ripening and labour induction, finding no significant differences in perinatal outcomes. A similar RCT by van Gemund et al  comparing vaginal misoprostol with prostaglandin E2 for induction of labour found similar rates of adverse neonatal outcome in both groups: 21% in the misoprostol and 23% in the prostaglandin E2 groups [LOE: 1+].An RCT by Rowlands et al.  comparing vaginal misoprostol and vaginal prostaglandin E2 for cervical priming prior to the induction of labour found no differences between the groups in low cord pH, Apgar score at delivery, or admission to the neonatal special care nursery [LOE: 1-].An RCT in Greece by Papanikolaou et al.  reported no statistically significant difference in perinatal mortality in babies born to women receiving vaginal misoprostol versus vaginal prostaglandin E2 (0/80 vs. 1/83 [1.2%], respectively) [LOE 1-].
Several other trials compared vaginal misoprostol to oxytocin and other prostaglandins administered via different administration routes. None reported any significant differences in impact on perinatal outcomes. An RCT in Sudan by Elhassan et al.  compared vaginal misoprostol to IV oxytocin and reported no difference in birth weight, Apgar score at birth, or stillbirth rates [LOE: 1-]. Meyer et al  found no difference in impact of a single outpatient dose of vaginal misoprostol (versus intracervical prostaglandin E2 gel) on subsequent use of oxytocin for induction, short-term neonatal outcome or rates of Caesarean delivery [LOE: 1+].A quasi-RCT in India  comparing vaginal misoprostol to Foley catheter for cervical dilatation plus IV oxytocin for induction of uterine contractions reported one stillbirth in the misoprostol group and none in the oxytocin plus Foley catheter group, but the sample size was too small to reach statistical significance [LOE: 2+]. A similar RCT of vaginal misoprostol versus IV oxytocin in Turkey by Sahin et al.  reported no intrapartum stillbirths in either group (0/50 in each group) [LOE: 1+].
Oral prostaglandins versus IV oxytocin
One Cochrane review by French et al.  (Additional file 10) compared oral prostaglandin E2 for third trimester induction of labour to IV oxytocin (2 RCTs, N = 35 women), reporting no perinatal deaths in either group (0/15 vs. 0/20 in prostaglandin E2 versus IV oxytocin groups, respectively).
Intracervical prostaglandins versus placebo
A Cochrane review by Boulvain et al.  (28 trials, N = 3764 women) comparing intracervical prostaglandins with placebo found a trend toward a lower PMR in the prostaglandin group but the result was not significant (RR [fixed] = 0.20, 95% CI: 0.01–4.05 [NS]) (Additional file 11). Prostaglandin E2 was associated with a decreased rate of labours lasting more than 24 hours versus placebo (4 trials, RR = 0.61, 95% CI: 0.47–0.79), but only a trend toward reduced risk of Caesarean section (RR = 0.88, 95% CI: 0.77–1.00). This decreased Caesarean section risk was statistically significant in the subgroup of women with intact membranes and unfavourable cervix (RR = 0.82; 95% CI: 0.68–0.98). The risk of hyperstimulation with fetal heart rate changes was not significantly increased (RR = 1.21; 95% CI: 0.72–2.05). However, the risk of hyperstimulation without fetal heart rate changes was significantly increased (RR = 1.59, 95% CI: 1.09–2.33) [LOE: 1+].
Vaginal prostaglandins versus placebo
Kelly et al.  conducted a Cochrane review to determine the effects of vaginal prostaglandins E2 and F2α for cervical ripening or induction of labour in comparison with placebo/no treatment, and reported a non-significant reduction in PMR (RR [fixed] = 0.56, 95% CI: 0.14–2.22 [NS])[ LOE: 1+](Additional file 12). One RCT compared vaginal prostaglandin E2 versus placebo , reporting no difference in fetal or neonatal outcomes or rates of Caesarean section [LOE: 2-].
Extra-amniotic prostaglandins versus placebo
A Cochrane review by Hutton et al.  compared the impact of extra-amniotic PGF2 versus extra-amniotic placebo gel for third trimester cervical ripening or induction of labour, and found no significant impact on PMR (RR [fixed] = 2.06, 95% CI: 0.09–46.11 [NS])[ LOE: 1++](Additional file 13).
Intravenous prostaglandins versus intravenous oxytocin
A Cochrane review by Luckas et al.  determined the effects of IV prostaglandin versus IV oxytocin for third trimester cervical ripening or induction of labour, and reported a non-significant trend toward increased risk of perinatal mortality with IV prostaglandin (RR [fixed] = 3.59, 95% CI: 0.60–21.53 [NS]) [LOE: 1+](Additional file 14).
Mifepristone versus placebo
A Cochrane analysis by Neilson  assessed the effectiveness of mifepristone, typically used to induce abortion or induce labour in cases of antepartum miscarriage or stillbirth, versus placebo in cervical softening and induction of labour (2 trials, N = 68 women). There were no perinatal deaths in either group (Additional file 15).
Vaginal misoprostol versus prostaglandin E2
We included 4 RCTs reporting perinatal death as outcome in a meta-analysis comparing vaginal misoprostol to prostaglandin E2 for inducing labour (N = 431 women; N = 216 misoprostol, N = 215 prostaglandin E2). We found no difference in perinatal death comparing misoprostol to prostaglandin E2 (RR [fixed] = 0.99, 95% CI: 0.14–7.13; RR [random] = 0.99, 95% CI: 0.10–9.45) (Figures 6 and 7).
Both vaginal and oral misoprostol are more effective than placebo and comparable to intravenous oxytocin or vaginal prostaglandin E2 in inducing labour at term [75, 79]. Misoprostol at any dosage carries higher risk of meconium staining, but this was not associated with any adverse perinatal outcomes. Compared with vaginal prostaglandins, oral misprostol appears to reduce rates of Caesarean section  and vaginal misoprostol is associated with shorter labour, fewer side effects, and lower incidence of retained placenta, with no difference in perinatal mortality. However, there remain questions about the safety of both vaginal and oral misoprostol because of a relatively high rate of uterine hyperstimulation and the lack of appropriate dose ranging studies. While no increase in adverse fetal outcomes was reported in any of the misoprostol studies, the number of adverse fetal outcomes was too few to draw meaningful conclusions. There is no evidence to support the selective use of either oral or vaginal misoprostol on either perinatal mortality or stillbirths.
There was no statistically significant impact of any prostaglandin preparation on perinatal outcomes; it should be noted that most studies reviewed were small and the numbers of adverse outcomes too small to accurately measure differences in stillbirth or perinatal mortality rates between study arms. Vaginal prostaglandin E2, especially as vaginal tablets, appears to be an effective labour induction agent, improving the likelihood of vaginal delivery within 24 hours and reducing the need for augmentation with oxytocin, without increasing the risk of Caesarean section . Vaginal prostaglandin E2 may reduce perinatal mortality, but the non-significant findings in the Cochrane review by Kelly et al indicate the need for further large RCTs. The intracervical mode of administration of prostaglandins is less used and less well evaluated than other modes of administration , and appears to be less effective in inducing labour than vaginal prostaglandin application, with no benefit for perinatal mortality. The data for perinatal mortality associated with extra-amniotic prostaglandins are extremely limited and require further trials .
Planned Caesarean section for breech presentation
Approximately 3–4% of term singleton pregnancies are complicated by breech presentation at term, and in most high-income countries, the majority of these births are handled via either planned or emergency Caesarean section. Whether planned caesarean section for breech presentation at term results in better perinatal outcomes is a contentious issue. An alternative to breech Caesarean section or breech vaginal delivery is external cephalic version, which has been shown to reduce numbers of breech births and breech Caesarean sections without impacting perinatal mortality [95, 96]. Until recently the major evidence for Caesarean section for breech presentation has been derived from patient case studies and register studies lacking sufficient rigor on which to make policy or clinical management recommendations. Here, we review the evidence for impact of planned Caesarean section for breech presentation on perinatal mortality and stillbirth rates.
Our literature search identified 1 Cochrane review and 3 other intervention/observational studies assessing the impact of planned Caesarean section for breech presentation on perinatal mortality outcomes (Table 6). The Cochrane review by Hofmeyr et al.  (Additional file 16) evaluated RCTs (3 trials, N = 2396 women), including the large Term Breech Trial , comparing planned Caesarean section with planned vaginal birth for singleton breech presentation at term. Perinatal or neonatal death (excluding fatal anomalies) or serious neonatal morbidity was reduced with planned Caesarean section compared to planned vaginal delivery [3/1166 (0.26%) vs. 14/1222 (1.15%), respectively; RR = 0.29, 95% CI: 0.10–0.86; 3 trials; N = 2388 women]. Compared with planned vaginal breech delivery, planned Caesarean section was associated with an increased risk of avoidable short-term maternal morbidity, including postpartum infection, haemorrhage, and anaemia (RR = 1.29, 95% CI: 1.03–1.61) [LOE: 1+].
In Switzerland, a cohort study by Irion et al.  of planned vaginal versus planned Caesarean section for breech singleton presentation at term (N = 705 women) found a non-significant increased risk of neonatal mortality among the group delivering vaginally, but all deaths were attributable to major malformations (1% vs. 0.3% in planned vaginal vs. Caesarean section groups, RR = 3.33, 95% CI: 0.37–29.60 [NS]) [LOE: 2-].
In The Netherlands, Molkenboer et al.  conducted a 2-centre retrospective matched cohort study including all singleton breech deliveries from 1998–2000 of at least 37 and less than 42 weeks' gestation, excluding antepartum stillbirths, but no perinatal deaths occurred in either group [LOE: 2-].
The above evidence for planned caesarean section delivery for singleton breech presentation at term indicates that this intervention is associated with a statistically significant reduction in perinatal and neonatal mortality and morbidity, though it is associated with increased short-term maternal morbidity associated with recovery from a Caesarean section. The largest study in the Cochrane review, the Term Breech Trial, demonstrates strong evidence of benefit of planned caesarean section in reducing perinatal mortality, though it should be noted that no point estimates for impact on stillbirths were reported. Additionally, a number of methodological and analytical criticisms have been levied at the largest study in the Cochrane review (the Term Breech Trial, whose principal investigator co-authored the Cochrane review) including a lack of adherence to inclusion criteria, great variability in level of care between facilities and labours (including insufficient monitoring in some cases), and a lack of clinicians with expertise in vaginal breech delivery, Glezerman M: Five years to the term breech trial: the rise and fall of a randomised controlled trial. Am J Obstet Gynecol 2006, 194:20-25.
Although planned Caesarean for breech presentation appears to be a promising intervention, in light of these criticisms and the downstream implications of recommending a policy of Caesarean section in low-resource settings, our recommendation for Caesarean section in term breech presentation carries several caveats. Given the risks associated with Caesarean section, a planned Caesarean section should only be considered after external cephalic version has been unsuccessful and sufficient time has been allowed for spontaneous version and cephalic birth to take place . Caesarean section poses short-term risks of infection and haemorrhage, as well as long-term risks including uterine rupture (particularly where a classical incision is performed), placental invasion of the uterine scar, stillbirth, and maternal death, for women who cannot or do not access facilities with comprehensive essential obstetric care in subsequent pregnancies. For these reasons, in some low-resource settings, the complications associated with Caesarean section may pose greater risks to both mothers' and babies' lives than vaginal delivery for breech presentation. Vaginal birth for breech presentations is advised in these circumstances, as 97% of breech-position singleton infants will be born without complications . Additionally, adoption of a policy of breech delivery by Caesarean section will ultimately lead to the disappearance of the specialised clinical skills required to perform vaginal breech delivery, meaning that women with breech fetuses who do deliver vaginally may face greater risk.
Magnesium sulphate supplementation for pre-eclampsia/eclampsia and pre-term labour
Magnesium sulphate has both anti-convulsant and tocolytic applications. Anti-convulsants, including magnesium sulphate, diazepam, and phenytoin, are a key strategy for preventing or stopping eclamptic seizures in pregnant women with pre-eclampsia and eclampsia, respectively, which account for 50,000 maternal deaths per year worldwide (10% of all direct maternal deaths) . Magnesium sulphate is generally regarded as the first choice drug, and superior to diazepam or phenytoin, for controlling eclamptic fits and preventing associated maternal and fetal deaths [102–104]. However, the use of magnesium sulphate presents potential hazards including severe maternal adverse effects such as respiratory and cardiac arrest, and risk of fetal neurological depression (e.g., decreased respiratory effort), suggesting that while magnesium sulphate may prevent some fetal and neonatal deaths due to eclampsia, it may present an increased risk of harm in some pregnancies.
Magnesium sulphate also has tocolytic properties: it relaxes smooth muscle and inhibits uterine contractile activity. Tocolytic drugs can theoretically prevent or delay labour and pre-term birth for women at high risk of pre-term delivery . Ideally, a tocolytic agent would delay labour long enough to administer corticosteroids to hasten fetal lung maturation prior to delivery. Magnesium sulphate is widely used as a tocolytic agent for preventing pre-term birth in the United States ; below, we explore the evidence for the impact of its use on stillbirth.
Our literature search identified 4 Cochrane reviews on the role of magnesium sulphate for management of pre-eclampsia and eclampsia and 3 Cochrane reviews and 1 other study on its role in threatened preterm labour (Table 7). The role of antenatal magnesium supplementation in prevention of pre-eclampsia in magnesium-deficient populations has been discussed in a previous paper in this series .
Magnesium sulphate for treatment of pre-eclampsia and eclampsia
A Cochrane review by Duley et al.  (Additional file 17) compared the impact of magnesium sulphate versus placebo or no treatment in women with pre-eclampsia, and reported no difference in the risk of stillbirth and/or neonatal death (3 trials; RR = 1.04, 95% CI: 0.93–1.15) [LOE: 1++]. A second Cochrane review by Duley et al.  (Additional file 18) comparing magnesium sulphate with diazepam in eclampsia cases showed no difference in stillbirth rates between the two treatments (RR = 0.89, 95% CI: 0.63–1.26); a separate Cochrane review  comparing magnesium sulphate to phenytoin found a similar non-significant impact on stillbirth rates (2 trials, 665 babies, RR = 0.83, 95% CI: 0.61–1.13). However, magnesium sulphate was associated with fewer admissions of babies to a neonatal special care unit (1 trial, N = 518 babies, RR = 0.73, 95% CI: 0.58–0.91), and fewer neonatal deaths or special care unit admissions exceeding 7 days (1 trial, N = 665 babies, RR = 0.77, 95% CI: 0.63–0.95) [LOE: 1+](Additional file 19).
Duley et al.  (Additional file 20) evaluated RCTs comparing any use of magnesium sulphate with any use of lytic cocktail (a combination of drugs, usually chlorpromazine, promethazine and pethidine) in women with eclampsia (2 trials, N = 199 women). Magnesium sulphate proved superior to lytic cocktail in preventing further seizures (RR = 0.09, 95% CI: 0.03–0.24), but the comparative impact of magnesium sulphate on stillbirths was not statistically significant (RR = 0.55, 95% CI-0.26–1.16) [LOE: 1+].
Magnesium sulphate for prevention of preterm birth
Doyle et al.  reviewed RCTs of studies evaluating the impact of antepartum magnesium sulphate therapy in women at high risk of, or with threatened, pre-term labour (4 trials, N = 3701 babies) (Additional file 21). There was no difference in risk of fetal death between women administered magnesium sulphate versus no magnesium sulphate (RR = 0.98, 95% CI: 0.78–1.24, 4 trials). Additionally, there was no impact of antepartum magnesium sulphate therapy on paediatric mortality (RR = 0.97, 95% CI: 0.74–1.28, 4 trials, 3701 infants) or neurological impairments or disabilities in early childhood [LOE: 1++].A second, large Cochrane review of the use of magnesium sulphate to prevent preterm birth by Crowther et al.  reported an elevated risk of baby death (fetal plus infant death) among infants exposed to magnesium sulphate (RR = 2.82, 95% CI: 1.20–6.62, 7 trials, 727 infants) (Additional file 22). Considering fetal deaths separately, there was no significant impact on risk of fetal death (1 trial, RR = 5.70, 95% CI: 0.28–116.87 [NS]); both fetal deaths occurred in just 1 of the 7 studies reporting fetal or child death. Magnesium sulphate made no difference in the risk of delivery within 48 hours of treatment (RR = 0.85, 95% CI: 0.58–1.25, 11 trials, 881 women) compared to controls not given magnesium sulphate. Similarly, no benefit was seen for magnesium sulphate on the risk of giving birth pre-term (<37 weeks) or very pre-term (<34 weeks). The third Cochrane review  on magnesium maintenance therapy after administration of an initial tocolytic for preventing preterm births, had 3 trials, including 303 women. The magnesium group had a five-fold higher risk of perinatal mortality than placebo, no or alternative treatment (Additional file 23).
A multicentre RCT of magnesium sulphate use to reduce cerebral palsy and death by Rouse et al.  in women at risk of preterm birth between 24 and 31 weeks of gestation showed that the women in the intervention group had a statistically non-significant slightly elevated risk of the composite outcome of stillbirth or infant death (RR = 1.12; 95% CI: 0.85–1.47). Risk of moderate or severe cerebral palsy was significantly lower in children of women given magnesium sulphate compared to placebo (RR = 0.55; 95% CI: 0.32–0.95) [LOE 1+].
Intravenous or intramuscular magnesium sulphate significantly decreases the risk of eclampsia. IV or intramuscular magnesium sulphate appears to be substantially more effective than diazepam and phenytoin for treatment of eclampsia, and is therefore the treatment of choice. No trials reported any statistically significant impact of magnesium sulphate on stillbirth incidence or perinatal mortality.
Among women deemed to be at risk of preterm birth, magnesium sulphate is ineffective at delaying or preventing labour, and while its use may be associated with side effects in the infant such as neurological depression, there is evidence that magnesium sulphate may also prevent moderate or severe cerebral palsy in live-born infants . There is not enough evidence to show any difference between magnesium maintenance therapy and either placebo or no treatment, or alternative therapies (other tocolytics, for example) in preventing preterm birth after an episode of threatened preterm labour. Thus, despite good quality evidence and impact on maternal pre-eclampsia (Grade A), evidence for impact of magnesium therapy on stillbirth prevention is insufficient.
Maternal hyperoxygenation for suspected impaired fetal growth
Long-term fetal hypoxia, which results from diminished oxygen and/or nutrient flow to the fetus from the mother, is often implicated in cases of impaired fetal growth. Impaired fetal growth may result from a number of factors, including fetal characteristics (e.g., congenital abnormalities), placental factors (e.g., small placenta, poor placentation), and maternal conditions (e.g., drug use, malnutrition, renal or vascular problems) . Severe deprivation of oxygen and/or nutrients can result in hypoxia or nutrient deprivation so severe as to cause stillbirth. Several observational uncontrolled trials have evaluated the physiological basis for maternal hyperoxygenation (40–55% humidified oxygen by face mask at 8 litres per minute, 24 hours per day) as a way to improve oxygen flow to the fetus and thereby alleviate hypoxia and stimulate nutrient transfer [114–118].
Our literature search identified 1 Cochrane review and 1 other intervention study (Table 8) that evaluated the impact of maternal hyperoxygenation on perinatal mortality. Say et al.  reviewed RCTs (3 RCTs, N = 94 women) comparing maternal oxygen therapy with no oxygen therapy in suspected impaired fetal growth, and found statistically significantly lower PMR in the oxygenation group compared to the non-oxygen group in all three included trials (RR = 0.50, 95% CI: 0.32–0.81). However, the reviewers cautioned that higher gestational age in the oxygenation groups might have accounted for the difference in mortality rates [LOE: 1++](Additional file 24).
A quasi-RCT by Battaglia et al.  attempted to compare the impact of maternal oxygenation versus no oxygen in a group of pregnant women (N = 38) prescribed bed rest, but no perinatal deaths occurred in either group [LOE: 2-].
The evidence for maternal hyperoxygenation in the Cochrane suggests that in pregnant women treated with long-term oxygen therapy, perinatal mortality is significantly reduced . Methodological deficiencies in the trials included in the Cochrane review, including the greater average gestational age of fetuses in the oxygen intervention groups and the small size of the included trials, suggest that this promising finding must be confirmed with rigorous, large multicentre RCTs reporting stillbirths and early neonatal mortality separately. Interestingly, while there appeared to be an impact on perinatal mortality, maternal hyperoxygenation did not appear to improve fetal growth. We classify maternal hyperoxygenation as having some evidence of benefit in reducing perinatal mortality given the promising findings of the Cochrane review on this subject, but suggest that this intervention not be included in programs until confirmatory results become available, as some prior studies have suggested that maternal hyperoxygenation may inadvertently reduce uterine blood flow, and that long-term oxygen therapy may be associated with maternal pulmonary dysfunction [121–123].
Amnioinfusion is a procedure whereby fluid (either saline or Ringer's lactate) is added to the uterine cavity transcervically via catheter, when the membranes have ruptured, or transabdominally using a needle if amniotic membranes are still intact. The procedure is often performed in an effort to prevent or relieve umbilical cord compression during labour associated with low amniotic fluid volume (oligohydramnios); the infusion of fluid also dilutes meconium detected in the amniotic fluid. Dilution of meconium is thought to minimize the risk of meconium aspiration, as thick meconium in cases of oligohydramnios is associated with significant perinatal mortality and morbidity . Amnioinfusion may impact fetal survival via one or both of these mechanisms and the two can be difficult to differentiate. Amnioinfusion has also been used in an effort to prevent ascending infection in cases of premature rupture of membranes (PROM), or to facilitate external cephalic version at term, though the impact of amnioinfusion for external cephalic version on perinatal outcomes has not been examined . The evidence for whether amnioinfusion for this variety of indications has any impact on perinatal mortality outcomes has not been systematically compiled.
The literature search identified 2 Cochrane reviews and 11 other interventional/observational studies, presented below by indication (Table 9).
Amnioinfusion for PROM
The original Cochrane review by Hofmeyr et al. on amnioinfusion  evaluated 14 relatively small (<200 participants) RCTs of amnioinfusion compared with no amnioinfusion in pregnancies with PROM as a treatment to alleviate umbilical cord compression and prevent intrauterine infection. There was no significant impact of amnioinfusion compared with controls on perinatal mortality (8 trials, RR = 0.51, 95% CI: 0.11–2.24) (Additional file 25). Transcervical amnioinfusion for potential or suspected umbilical cord compression reduced the risk of fetal heart rate decelerations (4 trials, N = 227 women: RR = 0.54; 95% CI: 0.43–0.68); Caesarean section (9 trials, N = 953 women, RR = 0.52, 95% CI: 0.40–0.69), Apgar score < 7 at 5 minutes (7 trials, N = 828 women, RR = 0.54, 95% CI: 0.30–0.97), and low cord arterial pH (6 trials, N = 660 women, RR = 0.45, 95% CI 0.31–0.64). Transabdominal amnioinfusion showed similar trends, though numbers studied were too small to reach statistical significance. Transcervical amnioinfusion to prevent infection in women with membranes ruptured for more than six hours (one trial of 66 women) was associated with a reduction in puerperal infection (1 trial, N = 68 women, RR = 0.50, CI 0.26–0.97) [LOE: 1-].
In a tertiary care facility in Italy, a quasi-RCT by De Santis et al. 2003  assessed the impact on fetal survival of weekly transabdominal amnioinfusion in a group of women with pre-term PROM at less than 26 weeks gestation (N = 71), reporting twice the survival rate among fetuses born to women in the amnioinfusion group versus the expectantly managed group (64.8% vs 32.3% of fetuses survived, respectively, P < 0.01).
Amnioinfusion for oligohydramnios with intact membranes
A case-control study of women with oligohydramnios in pregnancy (N = 100) by Chhabra et al.  administered antepartum transabdominal amnioinfusion to 50 women, treating the remainder conservatively. The perinatal mortality rate was significantly lower among the amnioinfusion group compared to controls given conservative management (4% vs. 18%, respectively) [LOE: 2++].
Prevention of meconium aspiration
A second Cochrane review by Hofmeyr  evaluated RCTs (12 small trials) comparing amnioinfusion with no amnioinfusion for women in labour under either normal or limited perinatal surveillance with moderate or thick meconium staining of the amniotic fluid (Additional file 26). Amnioinfusion was associated with significant reductions in heavy meconium staining of the amniotic fluid (RR = 0.03, 95% CI: 0.01–0.15) and variable fetal heart rate deceleration (RR = 0.65, 95% CI: 0.49–0.88). No perinatal deaths were reported. Under limited perinatal surveillance, amnioinfusion was associated with a trend towards reduced perinatal mortality (RR = 0.34, 95% CI: 0.11–1.06 [NS]), as well as significantly decreased risk of meconium aspiration syndrome (RR = 0.24, 95% CI: 0.12–0.48), neonatal hypoxic ischaemic encephalopathy (RR = 0.07, 95% CI: 0.01–0.56) and neonatal ventilation or intensive care unit admission (RR = 0.56, 95% CI: 0.39–0.79); [LOE: 1+].
A large, multicentre RCT (56 centres, 13 countries, N = 1998 women) by Fraser et al.  of transcervical amnioinfusion versus standard care in women with thick meconium staining reported 5 perinatal deaths in each group, suggesting no beneficial impact of amnioinfusion over standard care. The study also suggested the possibility that the risk of meconium aspiration syndrome could be elevated rather than reduced after amnioinfusion relative to controls (RR = 1.39, 0.88–2.19 [NS]).
A matched case-control study by Ashfaq and Shah  in Pakistan tested the impact of amnioinfusion in cases of meconium stained liquor (N = 400 women). Both perinatal morbidity and mortality were reduced in the amnioinfusion group relative to controls (6% vs. 14%, respectively), and the stillbirth rate was 0/200 (0%) in the amnioinfusion group versus 8/200 (4%) in the control group, though no statistical significance data was given. The prevalence of meconium aspiration syndrome was lower in the amnioinfusion group than among controls (22% vs. 56%, respectively).
Several relatively small studies on amnioinfusion for meconium staining in India reported lower rates of perinatal mortality in the amnioinfusion groups. A case-control study of amnioinfusion in women with meconium staining (N = 250) reported substantially fewer deaths in the amnioinfusion group than among controls (1/100 [1%] vs. 12/150 [8%], respectively, P = 0.01) . Kirubamani  tested the impact of intrapartum amnioinfusion with saline versus standard care in women with light, moderate, or thick meconium (N = 50), and documented no deaths in the intervention group versus one among controls (0/30 vs. 1/20, respectively). In West Bengal, a study by Das et al.  of women in labour with meconium-stained amniotic fluid (N = 150) found that the group that received transcervical amnioinfusion (N = 50) showed a possible trend toward reduced perinatal mortality compared to a group (N = 100) receiving standard care (4% vs. 13%, respectively; RR = 0.31; 95% CI: 0.07–1.31). Rathore  performed a trial of amnioinfusion during labour for women with meconium staining (N = 200), and found one stillbirth in the amnioinfusion group and one stillbirth and one neonatal death in the control group [LOE: 1+].
Our literature search identified ten randomised and quasi-randomised trials reporting an impact of amnioinfusion on stillbirths (9 trials, N = 1681 women) and perinatal mortality (10 trials, N = 3656 women). Pooled analysis of the impact of amnioinfusion on stillbirth incidence revealed a non-significant reduction in risk associated with amnioinfusion (RR [fixed] = 0.68, 95% CI: 0.19–2.41 [NS]; RR [random] = 0.69, 95% CI: 0.19–2.43 [NS]) (Figures 8 and 9). Comparing the impact of amnioinfusion versus controls without amnioinfusion on perinatal deaths yielded a trend toward reduced mortality (RR = 0.51, 95% CI: 0.25–1.04, RR [random] = 0.52, 95% CI: 0.25–1.09 [NS]) (Figures 10 and 11).
In low-resource settings, paediatric facilities for the management of meconium aspiration syndrome are scarce and interventions to prevent meconium aspiration are needed. Amnioinfusion, as one preventive option, is comparatively more feasible than management of meconium aspiration syndrome in settings with limited intrapartum facilities. Pooled data from the Hofmeyr meta-analysis support the use of amnioinfusion for meconium stained amniotic fluid to reduce the incidence of meconium aspiration syndrome, with a trend toward reduced perinatal mortality. However, the only large RCT on this subject by Fraser et al , performed after the Cochrane review, found no statistically significant impact on either meconium aspiration syndrome or perinatal mortality, suggesting the possibility of small study bias (an overrepresentation of published small trials favouring a treatment effect) in the Cochrane review .
For other antepartum and intrapartum indications for amnioinfusion, including PROM, oligohydramnios with intact membranes, alleviation of umbilical cord compression, and prevention of infection after membrane rupture, the available evidence is too limited to formulate recommendations on the use of amnioinfusion. Some small studies show promising differentials in mortality and other outcomes between intervention and control groups, but larger, more rigorous studies are needed to determine the impact of amnioinfusion on these outcomes.
Further studies of amnioinfusion are needed to confirm the obstetric indications and administration techniques by which amnioinfusion might reduce perinatal mortality. When performing amnioinfusion in low-resource settings, providers should remain vigilant about the risk of infection if aseptic conditions are not maintained.
While few studies reported consistent and statistically significant evidence of impact on perinatal mortality associated with the intrapartum interventions we reviewed, several interventions show promising indications of benefit for specific indications or in certain settings. Induction of labour rather than expectant management in post-term pregnancies showed strong evidence of impact, though the choice of drug(s) for induction of labour remains unclear. Planned Caesarean section for term breech presentation has been shown in a large RCT to reduce stillbirths three-fold compared to vaginal breech delivery, but questions of feasibility, potential enrolment bias, and consequences of implementing this intervention routinely in low-/middle-income countries prevent a universal recommendation for its practice. Magnesium sulphate for pre-eclampsia and eclampsia is effective in preventing eclamptic seizures, but studies, many underpowered, did not demonstrate an impact on perinatal mortality. Transcervical amnioinfusion for meconium staining appears promising for improving perinatal outcomes in low/middle income-country applications according to the findings of many small studies, but a large randomised trial of the intervention had no significant impact on perinatal mortality Other novel interventions like maternal hyperoxygenation had statistically significant evidence of impact on stillbirth, but the limited evidence base requires confirmation by other studies.
A distillation of the weight of the evidence for each of the 8 intrapartum interventions we reviewed is presented in Table 10.
Implications for programmes
While the implementation of any of the interventions examined in this paper could potentially prevent a stillbirth, multiple variables inherent to intrapartum care influence the outcome and complicate comparison between studies and assessment of the evidence of impact. Drug dosages, route of administration, and regimens often vary. The risk of a poor outcome of a forceps or vacuum extraction, or vaginal breech birth, is likely to be lower in the hands of an experienced versus an inexperienced practitioner. In the absence of adequate antisepsis or availability of clean water supplies and antibiotics, interventions such as instrumental delivery, Caesarean section and amnioinfusion may increase the risk of harm to the fetus or mother from infection, despite having been developed to save these lives. Monitoring quality and consistency during labour, prompt recognition of complications, and rapid performance of appropriate interventions while avoiding inappropriate interventions that put mother and fetus at unnecessarily increased risk are hallmarks of obstetric care quality that are difficult to assess, and likely varied, in the studies we reviewed.
The available evidence indicates broadly that where women receive high-quality intrapartum care, including monitoring of labour with access to operative delivery (instrumental delivery, whether forceps or vacuum, or Caesarean section), rates of perinatal deaths decrease. Particularly in low-resource settings, avoiding liberal use of Caesarean section, even for breech presentation at term, is advised.
Several interventions appear relatively well supported by the evidence. Timely delivery in the presence of intrapartum complications or maternal risk factors, often by Caesarean section or instrumental delivery, can reduce associated intrapartum stillbirth. This intervention is largely credited for the relatively low rates of intrapartum stillbirth in high-income countries . Induction of labour is beneficial at or after 41 or 42 weeks for post-term pregnancy, especially if early ultrasound dating was performed to confirm gestational age. Vacuum extraction and forceps have different risks and benefits, but use of either method is justified; more essential than the instrument chosen is the need for facilities to be equipped to provide safe instrumental delivery and Caesarean section.
Planned Caesarean section for breech delivery at term reduces perinatal mortality three-fold compared to vaginal breech delivery, and where most births are in facilities that can provide safe Caesarean section, the available evidence supports providers and their clients planning a Caesarean section for breech presentation with informed consent. In low-resource settings with poor access to EmOC, however, having a Caesarean scar introduces risk of subsequent poor pregnancy outcome and maternal death, so vaginal breech delivery should be encouraged, commensurate with skills of the birth attendants. Moreover, Goldenberg et al.  and McClure EM et al  showed that population-based rates of Caesarean section exceeding 10% had no further impact on stillbirth incidence.
As research of intrapartum interventions reporting stillbirth as a primary or secondary outcome is rarely conducted, many research gaps exist, making this an important area for future research (Table 11). None of the studies included in this review reported a consistent, statistically significant Grade A evidence of impact on stillbirth incidence. It follows that large RCTs (wherever ethically and logistically possible) powered to detect changes in stillbirth incidence are still needed for virtually all the interventions we reviewed.
In settings where safe, comprehensive EOC is already available, and diagnostic and monitoring capacity allow, advanced interventions to manage pre-eclampsia, PPROM, and oligohydramnios are needed. A few interventions examined in this review show strong evidence of impact for certain indications, including Caesarean for breech birth at term and induction of labour for post-term pregnancy. There is some evidence that other interventions such as amnioinfusion and maternal hyperoxygenation may reduce perinatal mortality, but further research on their safety and effectiveness in a range of settings is required before they can be routinely included in programs. In areas without comprehensive essential obstetric care capacity, it is key to prioritise improved access to EmOC, especially vacuum extraction and Caesarean section. EmOC is a package of clearly life-saving interventions, and there is an association between countries with high unmet obstetric need and intrapartum stillbirth rates . Safe EmOC, ideally as part of a package of comprehensive essential obstetric care services to address obstetric problems before they become emergencies, will have the greatest impact on intrapartum stillbirth rates in low-resource settings, though expanding provision of EmOC requires developing solutions for numerous logistical and infrastructural challenges. These interventions would need complementary measures to ensure staff training and optimise delivery strategies in health systems.
emergency obstetric care
essential obstetric care
low birth weight
neonatal mortality rate
perinatal mortality rate
randomised controlled trial
vaginal birth after Caesarean
World Health Organisation
Lawn J, Shibuya K, Stein C: No cry at birth: global estimates of intrapartum stillbirths and intrapartum-related neonatal deaths. Bulletin of the World Health Organization. 2005, 83 (6): 409-417.
World Health Organization: Neonatal and perinatal mortality. Country, regional and global estimates. Geneva, Switzerland. 2006
Goldenberg RL, McClure EM, Bann CM: The relationship of intrapartum and antepartum stillbirth rates to measures of obstetric care in developed and developing countries. Acta Obstet Gynecol Scand. 2007, 86 (11): 1303-1309. 10.1080/00016340701644876.
Stanton C, Lawn JE, Rahman H, Wilczynska-Ketende K, Hill K: Stillbirth rates: delivering estimates in 190 countries. The Lancet. 2006, 367: 1487-1494. 10.1016/S0140-6736(06)68586-3.
Lawn JE, Yakoob MY, Haws RA, Soomro T, Darmstadt GL, Bhutta ZA: 3.2 million stillbirths: epidemiology and overview of the evidence review. BMC Pregnancy and Childbirth. 2009, 9 (Suppl 1): S2-10.1186/1471-2393-9-S1-S2.
Majoko F, Gardener G: Trial of instrumental delivery in theatre versus immediate caesarean section for anticipated difficult assisted births. Cochrane Database Syst Rev. 2008, CD005545-4
Johanson RB, Menon V: Vacuum extraction versus forceps for assisted vaginal delivery. Cochrane Database of Systematic Reviews. 1999, CD000224-2
Johanson R, Menon V: Soft versus rigid vacuum extractor cups for assisted vaginal delivery. Cochrane Database Syst Rev. 2000, CD000446-2
Weerasekera DS, Premaratne S: A randomised prospective trial of the obstetric forceps versus vacuum extraction using defined criteria. J Obstet Gynaecol. 2002, 22 (4): 344-345. 10.1080/01443610220141227.
Mustafa R, Mustafa R: Perinatal and maternal outcome in ventouse versus forceps delivery. Journal of the College of Physicians & Surgeons Pakistan. 2002, 12 (6): 345-347.
Broekhuizen FF, Washington JM, Johnson F, Hamilton PR: Vacuum extraction versus forceps delivery: indications and complications, 1979 to 1984. Obstet Gynecol. 1987, 69 (3 Pt 1): 338-342.
Achanna S, Monga D: Outcome of forceps delivery versus vacuum extraction – a review of 200 cases. Singapore Med J. 1994, 35 (6): 605-608.
Gachiri JR, Rogo KO: Foetal and maternal outcome of vacuum extraction. East Afr Med J. 1991, 68 (7): 539-546.
Lurie S, Glezerman M, Baider C, Sadan O: Decision-to-delivery interval for instrumental vaginal deliveries: vacuum extraction versus forceps. Arch Gynecol Obstet. 2006, 274 (1): 34-36. 10.1007/s00404-005-0119-6.
Bhide A, Guven M, Prefumo F, Vankalayapati P, Thilaganathan B: Maternal and neonatal outcome after failed ventouse delivery: comparison of forceps versus cesarean section. J Matern Fetal Neonatal Med. 2007, 20 (7): 541-545. 10.1080/14767050701412297.
Benedetto C, Marozio L, Prandi G, Roccia A, Blefari S, Fabris C: Short-term maternal and neonatal outcomes by mode of delivery. A case-controlled study. Eur J Obstet Gynecol Reprod Biol. 2007, 135 (1): 35-40. 10.1016/j.ejogrb.2006.10.024.
Althabe F: Vacuum extraction versus forceps for assisted vaginal delivery: RHL commentary. The WHO Reproductive Health Library last revised: 14 November 2002. 2006, No 9, Update Software Ltd, Oxford
Belghiti A, De Brouwere V, Kegels G, Van Lerberghe W: Monitoring unmet obstetric need at district level in Morocco. Trop Med Int Health. 1998, 3 (7): 584-591. 10.1046/j.1365-3156.1998.00276.x.
Prytherch H, Massawe S, Kuelker R, Hunger C, Mtatifikolo F, Jahn A: The unmet need for emergency obstetric care in Tanga Region, Tanzania. BMC Pregnancy Childbirth. 2007, 7: 16-10.1186/1471-2393-7-16.
Smith GC, Fretts RC: Stillbirth. Lancet. 2007, 370 (9600): 1715-1725. 10.1016/S0140-6736(07)61723-1.
McClure EM, Goldenberg RL, Bann CM: Maternal mortality, stillbirth and measures of obstetric care in developing and developed countries. Int J Gynaecol Obstet. 2007, 96 (2): 139-146. 10.1016/j.ijgo.2006.10.010.
Campbell OM, Graham WJ: Lancet Maternal Survival Series steering group. Strategies for reducing maternal mortality: getting on with what works. Lancet. 2006, 368 (9543): 1284-1299. 10.1016/S0140-6736(06)69381-1.
Stanton M, Koblinsky M: Essential obstetric care and subsets – basic and emergency obstetric care: what's the difference? Policy Brief 1. 1999, Washington, DC: MotherCare
Mooney SE, Ogrinc G, Steadman W: Improving emergency caesarean delivery response times at a rural community hospital. Qual Saf Health Care. 2007, 16 (1): 60-66. 10.1136/qshc.2006.019976.
Cameron B: Outcomes in rural obstetrics, Atherton Hospital 1981–1990. Aust J Rural Health. 1998, 6 (1): 46-51. 10.1111/j.1440-1584.1998.tb00281.x.
Hueston WJ: A difference in cesarean rates between midwives and family physicians who worked in a shared practice. Birth. 1996, 23 (2): 116-10.1111/j.1523-536X.1996.tb00840.x.
Gray R, Quigley MA, Hockley C, Kurinczuk JJ, Goldacre M, Brocklehurst P: Caesarean delivery and risk of stillbirth in subsequent pregnancy: a retrospective cohort study in an English population. BJOG. 2007, 114 (3): 264-270. 10.1111/j.1471-0528.2006.01249.x.
Chalmers B, Wen SW: Perinatal Care in Canada. BMC Womens Health. 2004, 4 (Suppl 1): S28-10.1186/1472-6874-4-S1-S28.
Countdown to 2015. Tracking progress in maternal, newborn and child survival. The. 2008, The United Nations Children's Fund (UNICEF), Report
Leeman L, Leeman R: Do all hospitals need cesarean delivery capability? An outcomes study of maternity care in a rural hospital without on-site cesarean capability. J Fam Pract. 2002, 51 (2): 129-134.
Norris TE, Reese JW, Pirani MJ, Rosenblatt RA: Are rural family physicians comfortable performing cesarean sections?. J Fam Pract. 1996, 43 (5): 455-460.
Deutchman M, Connor P, Gobbo R, FitzSimmons R: Outcomes of cesarean sections performed by family physicians and the training they received: a 15-year retrospective study. J Am Board Fam Pract. 1995, 8 (2): 81-90.
McClure EM, Nalubamba-Phiri M, Goldenberg RL: Stillbirth in developing countries. Int J Gynaecol Obstet. 2006, 94 (2): 82-90. 10.1016/j.ijgo.2006.03.023.
World Health Organization: Appropriate technology for birth. Lancet. 1985, 2 (8452): 436-437.
Alessandri LM, Stanley FJ, Read AW: A case-control study of intrapartum stillbirths. Br J Obstet Gynaecol. 1992, 99 (9): 719-723.
Hankins GD, Clark SM, Munn MB: Cesarean section on request at 39 weeks: impact on shoulder dystocia, fetal trauma, neonatal encephalopathy, and intrauterine fetal demise. Semin Perinatol. 2006, 30 (5): 276-287. 10.1053/j.semperi.2006.07.009.
Bottoms SF, Paul RH, Iams JD, Mercer BM, Thom EA, Roberts JM, Caritis SN, Moawad AH, Van Dorsten JP, Hauth JC, et al: Obstetric determinants of neonatal survival: influence of willingness to perform cesarean delivery on survival of extremely low-birth-weight infants. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 1997, 176 (5): 960-966. 10.1016/S0002-9378(97)70386-7.
Iffy L, Apuzzio JJ, Mitra S, Evans H, Ganesh V, Zentay Z: Rates of cesarean section and perinatal outcome. Acta Obstet Gynecol Scand. 1994, 73 (3): 225-230. 10.3109/00016349409023444.
O'Driscoll K, Foley M, MacDonald D, Stronge J: Cesarean section and perinatal outcome: response from the House of Horne. Am J Obstet Gynecol. 1988, 158 (3 Pt 1): 449-452.
De Muylder X, Amy JJ: Caesarean section rates in an African country. Paediatr Perinat Epidemiol. 1993, 7 (3): 234-244. 10.1111/j.1365-3016.1993.tb00401.x.
Longombe AO, Wood PB, Dix R: Cesarean section – indications and risks in rural Zaire. Int J Gynaecol Obstet. 1990, 33 (3): 199-202. 10.1016/0020-7292(90)90001-2.
Kumar S, Maouris P: Induction of labour for trial of vaginal birth after caesarean section in a remote district hospital. Aust N Z J Obstet Gynaecol. 1996, 36 (4): 417-420. 10.1111/j.1479-828X.1996.tb02183.x.
Meehan FP, Burke G, Casey C, Sheil JG: Delivery following cesarean section and perinatal mortality. Am J Perinatol. 1989, 6 (1): 90-94. 10.1055/s-2007-999554.
Nyirjesy P, Nyirjesy KM: Vaginal birth after cesarean section in rural Zaire. Changing concepts. J Reprod Med. 1992, 37 (5): 457-460.
Mock CN, Visser L, Elkins TE, Wilson JB: Vaginal delivery after previous cesarean section in a rural West African hospital. Int J Gynaecol Obstet. 1991, 36 (3): 187-193. 10.1016/0020-7292(91)90712-E.
van Roosmalen J: Vaginal birth after cesarean section in rural Tanzania. Int J Gynaecol Obstet. 1991, 34 (3): 211-215. 10.1016/0020-7292(91)90351-5.
Ilesanmi OA, Sobowale OA, Marinho OA: Outcome of 441 breech singleton deliveries at the Catholic Hospital, Oluyoro, Ibadan. Afr J Med Med Sci. 1996, 25 (1): 41-46.
Gaffney G, Sellers S, Flavell V, Squier M, Johnson A: Case-control study of intrapartum care, cerebral palsy, and perinatal death. BMJ. 1994, 308 (6931): 743-750.
Lansky S, Franca E, Kawachi I: Social inequalities in perinatal mortality in Belo Horizonte, Brazil: the role of hospital care. Am J Public Health. 2007, 97 (5): 867-873. 10.2105/AJPH.2005.075986.
Lansky S, Subramanian SV, Franca E, Kawachi I: Higher perinatal mortality in National Public Health System hospitals in Belo Horizonte, Brazil, 1999: a compositional or contextual effect?. BJOG. 2007, 114 (10): 1240-1245. 10.1111/j.1471-0528.2007.01450.x.
Rautava L, Lehtonen L, Peltola M, Korvenranta E, Korvenranta H, Linna M, Hallman M, Andersson S, Gissler M, Leipala J, et al: The effect of birth in secondary- or tertiary-level hospitals in Finland on mortality in very preterm infants: a birth-register study. Pediatrics. 2007, 119 (1): e257-263. 10.1542/peds.2006-1964.
Goldenberg RL, Kirby R, Culhane JF: Stillbirth: a review. J Matern Fetal Neonatal Med. 2004, 16 (2): 79-94. 10.1080/14767050400003801.
Cruikshank DP, Linyear AS: Term stillbirth: causes and potential for prevention in Virginia. Obstet Gynecol. 1987, 69 (6): 841-844.
Korhonen J, Kariniemi V: Emergency cesarean section: the effect of delay on umbilical arterial balance and Apgar scores. Acta Obstet Gynecol Scand. 1994, 73 (10): 782-786. 10.3109/00016349409072505.
Jehan I, McClure EM, Salat S, Rizvi S, Pasha O, Harris H, Moss N, Goldenberg RL: Stillbirths in an urban community in Pakistan. Am J Obstet Gynecol. 2007, 197 (3): 257-10.1016/j.ajog.2007.07.012. e251–258.
Kiely JL, Paneth N, Susser M: Fetal death during labor: an epidemiologic indicator of level of obstetric care. Am J Obstet Gynecol. 1985, 153 (7): 721-727.
Abdel-Latif ME, Bajuk B, Oei J, Vincent T, Sutton L, Lui K: Does rural or urban residence make a difference to neonatal outcome in premature birth? A regional study in Australia. Arch Dis Child Fetal Neonatal Ed. 2006, 91 (4): F251-256. 10.1136/adc.2005.090670.
Steyn PS, Odendaal HJ, Steyn DW: Trends in caesarean sections at Tygerberg Hospital, South Africa: a 20 year experience. Cent Afr J Med. 1998, 44 (9): 219-223.
Grzybowski SC, Cadesky AS, Hogg WE: Rural obstetrics: a 5-year prospective study of the outcomes of all pregnancies in a remote northern community. CMAJ. 1991, 144 (8): 987-994.
MacDorman MF, Hoyert DL, Martin JA, Munson ML, Hamilton BE: Fetal and perinatal mortality, United States, 2003. Natl Vital Stat Rep. 2007, 55 (6): 1-17.
Smith GC, Pell JP, Cameron AD, Dobbie R: Risk of perinatal death associated with labor after previous cesarean delivery in uncomplicated term pregnancies. JAMA. 2002, 287 (20): 2684-2690. 10.1001/jama.287.20.2684.
Boulvain M, Kelly A, Irion O: Intracervical prostaglandins for induction of labour. Cochrane Database Syst Rev. 2008, CD006971-1
Irion O, M Boulvain: Induction of labour for suspected fetal macrosomia. Cochrane Database of Systematic Reviews. 1998, CD000938-2
Gulmezoglu AM, Crowther CA, Middleton P: Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev. 2006, CD004945-4
Boulvain M, Stan C, Irion O: Elective delivery in diabetic pregnant women. Cochrane Database Syst Rev. 2001, CD001997-2
Kjos SL, Henry OA, Montoro M, Buchanan TA, Mestman JH: Insulin-requiring diabetes in pregnancy: a randomized trial of active induction of labor and expectant management. Am J Obstet Gynecol. 1993, 169 (3): 611-615.
Dare MR, Middleton P, Crowther CA, Flenady VJ, Varatharaju B: Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database Syst Rev. 2006, CD005302-1
Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J: Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome (Protocol). Cochrane Database of Systematic Reviews. 2008, CD004735-2
da Graca Krupa F, Cecatti JG, de Castro Surita FG, Milanez HM, Parpinelli MA: Misoprostol versus expectant management in premature rupture of membranes at term. BJOG. 2005, 112 (9): 1284-1290. 10.1111/j.1471-0528.2005.00700.x.
Dodd JM, Crowther CA: Elective delivery of women with a twin pregnancy from 37 weeks' gestation. Cochrane Database Syst Rev. 2003, CD003582-1
Chattopadhyay SK, Sengupta BS, Edrees YB: Intracervical application of prostaglandin E2 tablets for elective induction of labor in grand multiparae: a prospective controlled study. Eur J Obstet Gynecol Reprod Biol. 1986, 22 (1–2): 7-15. 10.1016/0028-2243(86)90084-5.
Dyson DC, Miller PD, Armstrong MA: Management of prolonged pregnancy: induction of labor versus antepartum fetal testing. Am J Obstet Gynecol. 1987, 156 (4): 928-934.
Hannah ME, Hannah WJ, Hellmann J, Hewson S, Milner R, Willan A: Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group. N Engl J Med. 1992, 326 (24): 1587-1592.
Keirse MJ: Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience. J Reprod Med. 1993, 38 (1 Suppl): 89-100.
Alfirevic Z, Weeks A: Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2006, CD001338-2
Niromanesh S, Mosavi-Jarrahi A, Samkhaniani F: Intracervical Foley catheter balloon vs. prostaglandin in preinduction cervical ripening. Int J Gynaecol Obstet. 2003, 81 (1): 23-27. 10.1016/S0020-7292(02)00392-2.
Dalui R, Suri V, Ray P, Gupta I: Comparison of extraamniotic Foley catheter and intracervical prostaglandin E gel for preinduction cervical ripening. Acta Obstet Gynecol Scand. 2005, 84 (4): 362-367. 10.1111/j.0001-6349.2005.00662.x.
Sciscione AC, McCullough H, Manley JS, Shlossman PA, Pollock M, Colmorgen GH: A prospective, randomized comparison of Foley catheter insertion versus intracervical prostaglandin E2 gel for preinduction cervical ripening. Am J Obstet Gynecol. 1999, 180 (1 Pt 1): 55-60. 10.1016/S0002-9378(99)70149-3.
Hofmeyr GJ, Gulmezoglu AM: Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2003, CD000941-1
Garry D, Figueroa R, Kalish RB, Catalano CJ, Maulik D: Randomized controlled trial of vaginal misoprostol versus dinoprostone vaginal insert for labor induction. J Matern Fetal Neonatal Med. 2003, 13 (4): 254-259. 10.1080/713605867.
Lokugamage AU, Forsyth SF, Sullivan KR, El Refaey H, Rodeck CH: Dinoprostone versus misoprostol: a randomized study of nulliparous women undergoing induction of labor. Acta Obstet Gynecol Scand. 2003, 82 (2): 133-137. 10.1034/j.1600-0412.2003.00066.x.
van Gemund N, Scherjon S, LeCessie S, van Leeuwen JH, van Roosmalen J, Kanhai HH: A randomised trial comparing low dose vaginal misoprostol and dinoprostone for labour induction. BJOG. 2004, 111 (1): 42-49. 10.1046/j.1471-0528.2003.00010.x.
Rowlands S, Bell R, Donath S, Morrow S, Trudinger BJ: Misoprostol versus dinoprostone for cervical priming prior to induction of labour in term pregnancy: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2001, 41 (2): 145-152. 10.1111/j.1479-828X.2001.tb01199.x.
Papanikolaou EG, Plachouras N, Drougia A, Andronikou S, Vlachou C, Stefos T, Paraskevaidis E, Zikopoulos K: Comparison of misoprostol and dinoprostone for elective induction of labour in nulliparous women at full term: a randomized prospective study. Reprod Biol Endocrinol. 2004, 2: 70-10.1186/1477-7827-2-70.
Elhassan EM, Mirghani OA, Adam I: Misoprostol vs. oxytocin for induction of labor. Int J Gynaecol Obstet. 2005, 91 (3): 254-255. 10.1016/j.ijgo.2005.08.003.
Meyer M, Pflum J, Howard D: Outpatient misoprostol compared with dinoprostone gel for preinduction cervical ripening: a randomized controlled trial. Obstet Gynecol. 2005, 105 (3): 466-472.
Jindal P, Gill BK, Tirath B: A comparison of vaginal misoprostol versus Foley's catheter with oxytocin for induction of labor. Journal of Obstetrics and Gynaecology of India. 2007, 57 (1): 42-47.
Sahin HG, Sahin HA, Kocer M: Induction of labor in toxemia with misoprostol. Acta Obstet Gynecol Scand. 2002, 81 (3): 252-257. 10.1034/j.1600-0412.2002.810311.x.
French L: Oral prostaglandin E2 for induction of labour. Cochrane Database Syst Rev. 2001, CD003098-2
Kelly AJ, Kavanagh J, Thomas J: Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2003, CD003101-4
Sahraoui W, Hajji S, Bibi M, Nouira M, Essaidi H, Khairi H: [Management of pregnancies beyond forty-one week's gestation with an unfavorable cervix]. J Gynecol Obstet Biol Reprod (Paris). 2005, 34 (5): 454-462.
Hutton E, Mozurkewich E: Extra-amniotic prostaglandin for induction of labour. Cochrane Database Syst Rev. 2001, CD003092-2
Luckas M, Bricker L: Intravenous prostaglandin for induction of labour. Cochrane Database Syst Rev. 2000, CD002864-4
Neilson JP: Mifepristone for induction of labour. Cochrane Database Syst Rev. 2000, CD002865-4
Hofmeyr GJ, Kulier R: External cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2000, CD000083-2
Lau TK, Lo KW, Rogers M: Pregnancy outcome after successful external cephalic version for breech presentation at term. Am J Obstet Gynecol. 1997, 176 (1 Pt 1): 218-223. 10.1016/S0002-9378(97)80040-3.
Hofmeyr GJ, Hannah ME: Planned caesarean section for term breech delivery. Cochrane Database Syst Rev. 2003, CD000166-3
Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR: Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet. 2000, 356 (9239): 1375-1383. 10.1016/S0140-6736(00)02840-3.
Irion O, Hirsbrunner Almagbaly P, Morabia A: Planned vaginal delivery versus elective caesarean section: a study of 705 singleton term breech presentations. Br J Obstet Gynaecol. 1998, 105 (7): 710-717.
Molkenboer JF, Vencken PM, Sonnemans LG, Roumen FJ, Smits F, Buitendijk SE, Nijhuis JG: Conservative management in breech deliveries leads to similar results compared with cephalic deliveries. J Matern Fetal Neonatal Med. 2007, 20 (8): 599-603. 10.1080/14767050701449703.
Duley L: Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992, 99 (7): 547-553.
Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995, 345 (8963): 1455-1463.
Duley L, Henderson-Smart D: Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2003, CD000127-4
Duley L, Henderson-Smart D: Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2003, CD000128-4
Crowther CA, Hiller JE, Doyle LW: Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev. 2002, CD001060-4
Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG: Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002, 186 (6): 1111-1118. 10.1067/mob.2002.123544.
Yakoob MY, Menezes EV, Soomro T, Haws RA, Darmstadt GL, Bhutta ZA: Reducing stillbirths: behavioural and nutritional interventions before and during pregnancy. BMC Pregnancy and Childbirth. 2009, 9 (Suppl 1): S3-10.1186/1471-2393-9-S1-S3.
Duley L, Gulmezoglu AM, Henderson-Smart DJ: Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2003, CD000025-2
Duley L, Gulmezoglu AM: Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database of Systematic Reviews. 2000, CD002960-3
Doyle LW, Crowther CA, Middleton P, Marret S: Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2007, CD004661-3
Crowther CA, Moore V: Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews. 1998, CD000940-1
Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, et al: A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008, 359 (9): 895-905. 10.1056/NEJMoa0801187.
Resnik R: Intrauterine growth restriction. Obstet Gynecol. 2002, 99 (3): 490-496. 10.1016/S0029-7844(01)01780-X.
Rasanen J, Wood DC, Debbs RH, Cohen J, Weiner S, Huhta JC: Reactivity of the human fetal pulmonary circulation to maternal hyperoxygenation increases during the second half of pregnancy: a randomized study. Circulation. 1998, 97 (3): 257-262.
Caforio L, Caruso A, Testa AC, Pompei A, Ciampelli M: Short-term maternal oxygen administration in fetuses with absence or reversal of end-diastolic velocity in umbilical artery: pathophysiological and clinical considerations. Acta Obstet Gynecol Scand. 1998, 77 (7): 707-711. 10.1034/j.1600-0412.1998.770702.x.
Simchen MJ, Tesler J, Azami T, Preiss D, Fedorko L, Goldszmidz E, Fisher J, Kingdom J, Slorach C, Hornberger LK: Effects of maternal hyperoxia with and without normocapnia in uteroplacental and fetal Doppler studies. Ultrasound Obstet Gynecol. 2005, 26 (5): 495-499. 10.1002/uog.1995.
Battaglia C, Artini PG, D'Ambrogio G, Galli PA, Segre A, Genazzani AR: Maternal hyperoxygenation in the treatment of intrauterine growth retardation. Am J Obstet Gynecol. 1992, 167 (2): 430-435.
Lindow S, Mantel G, Anthony J, Coetzee E, Pharoah P: A double blind randomised controlled trial of continuous oxygen therapy for compromised fetuses. Journal of Perinatal Medicine. 2001, 29 (Suppl 1): 123-
Say L, Gulmezoglu AM, Hofmeyr GJ: Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev. 2003, CD000137-1
Battaglia C, Artini PG, D'Ambrogio G, Bencini S, Galli PA, Genazzani AR: Maternal hyperoxygenation in the treatment of mild intrauterine growth retardation: a pilot study. Ultrasound Obstet Gynecol. 1994, 4 (6): 472-475. 10.1046/j.1469-0705.1994.04060472.x.
Johanson R, Lindow S, Elst van der C, Westhuizen van der S, Tucker A, Jaquire Z: RCT of maternal oxygen therapy for in-utero asphyxia. Proceedings of 2nd International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists:. 1993, Sept 7–10; Hong Kong
Tervila L, Vartiainen E, Kivalo I, Finnila MJ, Vayrynen M: The effect of oxygen ventilation and vasodilator on uterine perfusion, fetal oxygen and acid-base balance. I. A study in abnormal gravidae. Acta Obstet Gynecol Scand. 1973, 52 (4): 309-315.
Tervila L, Vartianinen E, Kivalo I, Finnila MJ, Vayrynen M: The effect of oxygen ventilation and a vasodilator on uterine perfusion, foetal oxygen and acid-base balance. I. A study in healthy gravidae. Acta Obstet Gynecol Scand. 1973, 52 (2): 177-181.
Hofmeyr GJ: Amnioinfusion for meconium-stained liquor in labour. Cochrane Database Syst Rev. 2002, CD000014-1
Hofmeyr G: Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database of Systematic Reviews. 1998, CD000013-1
Hofmeyr GJ: Interventions to help external cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2004, CD000184-1
De Santis M, Scavo M, Noia G, Masini L, Piersigilli F, Romagnoli C, Caruso A: Transabdominal amnioinfusion treatment of severe oligohydramnios in preterm premature rupture of membranes at less than 26 gestational weeks. Fetal Diagn Ther. 2003, 18 (6): 412-417. 10.1159/000073134.
Chhabra S, Dargan R, Nasare M: Antepartum transabdominal amnioinfusion. Int J Gynaecol Obstet. 2007, 97 (2): 95-99. 10.1016/j.ijgo.2006.06.009.
Fraser WD, Hofmeyr J, Lede R, Faron G, Alexander S, Goffinet F, Ohlsson A, Goulet C, Turcot-Lemay L, Prendiville W, et al: Amnioinfusion for the prevention of the meconium aspiration syndrome. N Engl J Med. 2005, 353 (9): 909-917. 10.1056/NEJMoa050223.
Ashfaq F, Shah AA: Effect of amnioinfusion for meconium stained amniotic fluid on perinatal outcome. J Pak Med Assoc. 2004, 54 (6): 322-325.
Sahu L, Induvadani M: Intrapartum amnioinfusion for meconium stained amniotic fluid. J Obstet Gynaecol India. 2003, 53: 345-347.
Kirubamani : A fetal therapy in labour with meconium stained liquor. International Journal of Gynecology & Obstetrics. 2000, 70 (Supp 2): B125-10.1016/S0020-7292(00)83096-9.
Das AK, Jana N, Dasgupta S, Samanta B: Intrapartum transcervical amnioinfusion for meconium-stained amniotic fluid. Int J Gynaecol Obstet. 2007, 97 (3): 182-186. 10.1016/j.ijgo.2007.01.006.
Rathore AM, Singh R, Ramji S, Tripathi R: Randomized trial of amnioinfusion during labour with meconium stained amniotic fluid. Br J Obstet Gynaecol. 2002, 109: 17-20.
Hemming K, Hutton JL: Intrapartum amnioinfusion for meconium-stained amniotic fluid: evidence for small study effect bias?. BJOG. 2009, 116 (1): 128-129. 10.1111/j.1471-0528.2008.02011.x.
Mesleh RA, Al-Sawadi HM, Kurdi AM: Comparison of maternal and infant outcomes between vacuum extraction and forceps deliveries. Saudi Med J. 2002, 23 (7): 811-813.
McClure EM, Wright LL, Goldenberg RL, Goudar SS, Parida SN, Jehan I, Tshefu A, Chomba E, Althabe F, Garces A, et al: The global network: a prospective study of stillbirths in developing countries. Am J Obstet Gynecol. 2007, 197 (3): 247-10.1016/j.ajog.2007.07.004. e241–245.
Mekbib TA, Teferi B: Caesarean section and foetal outcome at Yekatit 12 Hospital, Addis Abeba, Ethiopia, 1987–1992. Ethiop Med J. 1994, 32 (3): 173-179.
Wright EA, Kapu MM, Onwuhafua HI: Perinatal mortality and cesarean section in Jos University Teaching Hospital, Nigeria. Int J Gynaecol Obstet. 1991, 35 (4): 299-304. 10.1016/0020-7292(91)90661-N.
Abate M, Lakew Z: Eclampsia a 5 years retrospective review of 216 cases managed in two teaching hospitals in Addis Ababa. Ethiop Med J. 2006, 44 (1): 27-31.
Basso O, Rasmussen S, Weinberg CR, Wilcox AJ, Irgens LM, Skjaerven R: Trends in fetal and infant survival following preeclampsia. JAMA. 2006, 296 (11): 1357-1362. 10.1001/jama.296.11.1357.
Bhattacharyya M, Companywalla R, Shinde S, Purandare VN: Active management of high-risk pregnancy. Int J Gynaecol Obstet. 1979, 17 (3): 278-280.
Onyiriuka AN: High birth weight babies: incidence and foetal outcome in a mission hospital in Benin City, Nigeria. Niger J Clin Pract. 2006, 9 (2): 114-119.
Ananth CV, Joseph KS, Kinzler WL: The influence of obstetric intervention on trends in twin stillbirths: United States, 1989–99. J Matern Fetal Neonatal Med. 2004, 15 (6): 380-387. 10.1080/14767058410001727413.
Fakeye O: Breech births in twin pregnancy: an analysis of Apgar score and perinatal mortality from a Nigerian sample. Int J Gynaecol Obstet. 1988, 27 (1): 11-16. 10.1016/0020-7292(88)90081-1.
Rydhstrom H, Ingemarsson I: A case-control study of the effects of birth by caesarean section on intrapartum and neonatal mortality among twins weighing 1500 – 2499 g. Br J Obstet Gynaecol. 1991, 98 (3): 249-253.
Smith GC, Shah I, White IR, Pell JP, Dobbie R: Mode of delivery and the risk of delivery-related perinatal death among twins at term: a retrospective cohort study of 8073 births. BJOG. 2005, 112 (8): 1139-1144.
Smith GC, Fleming KM, White IR: Birth order of twins and risk of perinatal death related to delivery in England, Northern Ireland, and Wales, 1994–2003: retrospective cohort study. BMJ. 2007, 334 (7593): 576-10.1136/bmj.39118.483819.55.
Bahtiyar MO, Julien S, Robinson JN, Lumey L, Zybert P, Copel JA, Lockwood CJ, Norwitz ER: Prior cesarean delivery is not associated with an increased risk of stillbirth in a subsequent pregnancy: analysis of U.S. perinatal mortality data, 1995–1997. Am J Obstet Gynecol. 2006, 195 (5): 1373-1378.
Duff C, Sinclair M: Exploring the risks associated with induction of labour: a retrospective study using the NIMATS database. Northern Ireland Maternity System. J Adv Nurs. 2000, 31 (2): 410-417. 10.1046/j.1365-2648.2000.01335.x.
Majoko F, Zwizwai M, Lindmark G, Nystrom L: Labor induction with vaginal misoprostol and extra-amniotic prostaglandin F2alpha gel. Int J Gynaecol Obstet. 2002, 76 (2): 127-133. 10.1016/S0020-7292(01)00570-7.
Nalliah S, Loh KY, Japaraj RP, Mukudan K: Is there a place for selective vaginal breech delivery in Malaysian hospitals: experiences from the Ipoh hospital. J Matern Fetal Neonatal Med. 2009, 22 (2): 129-136. 10.1080/14767050802509520.
Mukhopadhyay P, Naskar T, Dalui R, Hazra S, Guin K, Bhattacharya D: Role of intrapartum amnioinfusion in meconium stained amniotic fluid. J Obstet Gynaecol India. 2006, 56: 230-232.
Das V, Srivastava S, Kumar P, Malik GK, Kumar M: Amnioinfusion during labour complicated by meconium. J Obstet Gynaecol India. 2001, 51: 105-107.
Halvax L, Szabo I, Vizer M, Csermely T, Ertl T: Simultaneous use of intrapartum fetal pulse oximetry and amnioinfusion in meconium stained amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2002, 104 (2): 105-108. 10.1016/S0301-2115(02)00061-1.
This series was supported by the Saving Newborn Lives programme of Save the Children-US through a grant from the Bill & Melinda Gates Foundation.
This article has been published as part of BMC Pregnancy and Childbirth Volume 9 Supplement 1, 2009: Stillbirths – the global picture and evidence-based solutions. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2393/9?issue=S1.
The authors declare that they have no competing interests.
The paper was written and reviewed by all the authors.